PMID- 34637322
OWN - NLM
STAT- MEDLINE
DCOM- 20220321
LR  - 20220531
IS  - 1545-4304 (Electronic)
IS  - 0362-1642 (Linking)
VI  - 62
DP  - 2022 Jan 6
TI  - Brain-Protective Mechanisms of Transcription Factor NRF2: Toward a Common 
      Strategy for Neurodegenerative Diseases.
PG  - 255-277
LID - 10.1146/annurev-pharmtox-052220-103416 [doi]
AB  - Neurodegenerative diseases are characterized by the loss of homeostatic functions 
      that control redox and energy metabolism, neuroinflammation, and proteostasis. 
      The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is a 
      master controller of these functions, and its overall activity is compromised 
      during aging and in these diseases. However, NRF2 can be activated 
      pharmacologically and is now being considered a common therapeutic target. Many 
      gaps still exist in our knowledge of the specific role that NRF2 plays in 
      specialized brain cell functions or how these cells respond to the hallmarks of 
      these diseases. This review discusses the relevance of NRF2 to several hallmark 
      features of neurodegenerative diseases and the current status of pharmacological 
      activators that might pass through the blood-brain barrier and provide a 
      disease-modifying effect.
FAU - Cuadrado, Antonio
AU  - Cuadrado A
AD  - Department of Biochemistry, Medical College, Autonomous University of Madrid, 
      Madrid 28049, Spain.
AD  - Instituto de Investigaciones Biomedicas "Alberto Sols" (CSIC-UAM), Madrid 28029, 
      Spain.
AD  - Instituto de Investigacion Sanitaria La Paz (IdiPaz), Madrid 28046, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas 
      (CIBERNED), Madrid 28031, Spain; email: Antonio.cuadrado@uam.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20211012
PL  - United States
TA  - Annu Rev Pharmacol Toxicol
JT  - Annual review of pharmacology and toxicology
JID - 7607088
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (NFE2L2 protein, human)
SB  - IM
MH  - Aging
MH  - Brain/metabolism
MH  - Humans
MH  - *NF-E2-Related Factor 2/metabolism
MH  - *Neurodegenerative Diseases/drug therapy/metabolism
MH  - Oxidative Stress
OTO - NOTNLM
OT  - electrophiles
OT  - metabolism
OT  - neurodegenerative diseases
OT  - neuroinflammation
OT  - oxidative stress
OT  - proteostasis
EDAT- 2021/10/13 06:00
MHDA- 2022/03/22 06:00
CRDT- 2021/10/12 17:13
PHST- 2021/10/13 06:00 [pubmed]
PHST- 2022/03/22 06:00 [medline]
PHST- 2021/10/12 17:13 [entrez]
AID - 10.1146/annurev-pharmtox-052220-103416 [doi]
PST - ppublish
SO  - Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:255-277. doi: 
      10.1146/annurev-pharmtox-052220-103416. Epub 2021 Oct 12.